G Belcher

Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry

Wern Yew Ding, Marco Proietti, Giuseppe Boriani, Laurent Fauchier et autres

AIMS: The 4S-AF classification scheme comprises of four domains: stroke risk (St), symptoms (Sy), severity of atrial fibrillation (AF) burden (Sb), and substrate (Su). We sought to examine the implementation of the 4S-AF scheme in the EORP-AF General Long-Term Registry and compare …

gb, it, fr, se, es, rs, dk (code pays fourni par la source)

Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC–EHRA EORP AF Long-Term General Registry

Wern Yew Ding, Giuseppe Boriani, Francisco Marı́n, Carina Blomström‐Lundqvist et autres

AIMS: The safety of digoxin therapy in atrial fibrillation (AF) remains ill-defined. We aimed to evaluate the effects of digoxin over beta-blocker therapy in AF. METHODS AND RESULTS: Patients with AF who were treated with either digoxin or a beta blocker from …

gb, it, es, se, rs, fr, dk (code pays fourni par la source)

Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).

H Oberender, T. Krais, Matthieu Schäfer, G Belcher